Evidence map›Paper›PMID 30740687›Full record

ArticleJournal of cellular physiology2019

Defining early hematopoietic-fated primitive streak specification of human pluripotent stem cells by the orchestrated balance of Wnt, activin, and BMP signaling.

Jun Shen, Cuicui Lyu, Yaoyao Zhu, Zicen Feng, Shuo Zhang, Dixie L Hoyle, Guangzhen Ji, Robert A Brodsky, Tao Cheng, Zack Z Wang

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Journal of cellular physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. iScience · 2024
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Jun ShenState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China.
Cuicui LyuDepartment of Hematology, the First Central Hospital of Tianjin, Tianjin, China.
Yaoyao ZhuState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China.
Zicen FengState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China.
Shuo ZhangState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China.
Dixie L HoyleDivision of Hematology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Guangzhen JiState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China.
Robert A BrodskyDivision of Hematology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Tao ChengState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China.
Zack Z WangDivision of Hematology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID http://orcid.org/0000-0002-6702-2648
Johns Hopkins University · USInstitute of Hematology & Blood Diseases Hospital · CNCell Technology (China) · CNTianjin First Center Hospital · CN

Funding

Generation of engraftable HSPCs from hemogenic endothelial cellsR01DK106109 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI WANG, ZACK Z. · 2016 to 2018
$875k
CAMS Initiative for Innovative Medicine 2016-I2M-1-017Chun Miao Foundation of the First Central Hospital of Tianjin TFCHCM201808Ministry of Science and Technology of China 2015CB964902National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease grant R01DK106109 (Z.W)National Key Research and Development Program of China Stem Cell and Translational Research 2016YFA0100600National Key Research and Development Program of China Stem Cell and Translational Research 2017YFA0103102National Key Research and Development Program of China Stem Cell and Translational Research 2017YFA0103400National Natural Science Foundation of China 81421002NIDDK NIH HHS R01 DK106109
6 · The paper itself

Abstract

Distinct regions of the primitive streak (PS) have diverse potential to differentiate into several tissues, including the hematopoietic lineage originated from the posterior region of PS. Although various signaling pathways have been identified to promote the development of PS and its mesoderm derivatives, there is a large gap in our understanding of signaling pathways that regulate the hematopoietic fate of PS. Here, we defined the roles of Wnt, activin, and bone morphogenetic protein (BMP) signaling pathways in generating hematopoietic-fated PS from human pluripotent stem cells (hPSCs). We found that the synergistic balance of these signaling pathways was crucial for controlling the PS fate determination towards hematopoietic lineage via mesodermal progenitors. Although the induction of PS depends largely on the Wnt and activin signaling, the PS generated without BMP4 lacks the hematopoietic potential, indicating that the BMP signaling is necessary for the PS to acquire hematopoietic property. Appropriate levels of Wnt signaling is crucial for the development of PS and its specification to the hematopoietic lineage. Although the development of PS is less sensitive to activin or BMP signaling, the fate of PS to mesoderm progenitors and subsequent hematopoietic lineage is determined by appropriate levels of activin or BMP signaling. Collectively, our study demonstrates that Wnt, activin, and BMP signaling pathways play cooperative and distinct roles in regulating the fate determination of PS for hematopoietic development. Our understanding of the regulatory networks of hematopoietic-fated PS would provide important insights into early hematopoietic patterning and possible guidance for generating functional hematopoietic cells from hPSCs in vitro.

Indexed as

hematopoietic differentiationhuman pluripotent stem cellsmesodermprimitive streaksignaling pathways

Identifiers

PMID30740687
PMCPMC6689260
OpenAlexW2914307626

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.